Medicare Insurance Appeals: Process and Levels of Review

Medicare insurance appeals follow a structured, federally mandated process that governs how beneficiaries challenge coverage denials, claim rejections, and service terminations across Medicare Parts A, B, C, and D. The five-level appeals system is codified in federal regulations and administered by multiple agencies, including the Centers for Medicare & Medicaid Services (CMS) and the Office of Medicare Hearings and Appeals (OMHA). Understanding how each level operates, what triggers escalation, and where disputes are most likely to stall is essential for beneficiaries, providers, and advocates navigating the system.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps
• Reference Table or Matrix
• References

Definition and Scope

A Medicare insurance appeal is a formal request by a beneficiary, authorized representative, or provider to review a coverage or payment determination made by Medicare or a Medicare-contracted plan. The legal basis for this process is established in the Social Security Act, specifically 42 U.S.C. § 1395ff for Parts A and B, and 42 U.S.C. § 1395w-22(g) for Medicare Advantage (Part C). Part D prescription drug appeals are governed under 42 C.F.R. Part 423, Subpart M (Electronic Code of Federal Regulations, 42 CFR Part 423).

The scope of appealable decisions includes initial coverage determinations, redeterminations, claim denials based on medical necessity, prior authorization denials, termination of covered services, and formulary exceptions for Part D drugs. Original Medicare (Parts A and B) and Medicare Advantage (Part C) follow separate but parallel appeal pathways, with some shared escalation infrastructure. Part D operates on a distinct track, though it ultimately merges with the broader federal administrative review system at higher levels.

Appeals are not limited to beneficiaries. Providers and suppliers who accept assignment on a Medicare claim hold independent appeal rights under 42 C.F.R. § 405.906 (CMS, Medicare Claims Processing Manual, Chapter 29).

For a broader orientation to federal insurance appeal rights, the regulatory framework extends well beyond Medicare into ERISA-governed and ACA-marketplace contexts.

Core Mechanics or Structure

The Medicare appeals system operates through 5 sequential levels. Each level must generally be exhausted before advancing to the next, and specific dollar thresholds govern access to certain levels.

Level 1 — Redetermination
Conducted by the Medicare Administrative Contractor (MAC) that issued the initial determination. Governed by 42 C.F.R. § 405.940–405.958. The request must be filed within 120 calendar days of receiving the initial determination notice. MACs have 60 days to issue a redetermination for standard claims.

Level 2 — Reconsideration by a Qualified Independent Contractor (QIC)
If the MAC redetermination is unfavorable, the case moves to an independent QIC. Filing must occur within 180 days of the MAC's redetermination notice. QICs have 60 days for standard reviews. For expedited appeals involving ongoing care, the QIC has 72 hours (42 C.F.R. § 405.970–405.1006).

Level 3 — Administrative Law Judge (ALJ) Hearing
Administered by the Office of Medicare Hearings and Appeals (OMHA). Access to this level requires that the amount in controversy (AIC) meet a minimum threshold, adjusted annually — set at $180 in 2023 per OMHA (OMHA ALJ Hearing Threshold, CMS.gov). Filing deadline is 60 days from the QIC reconsideration notice.

Level 4 — Medicare Appeals Council (MAC Council)
Review is conducted by the Departmental Appeals Board (DAB) within the Department of Health and Human Services. Filing must occur within 60 days of the ALJ decision. The Council may review ALJ decisions on its own motion or upon request.

Level 5 — Federal District Court
Available only when the AIC meets a threshold adjusted annually — $1,760 in 2023 per CMS (CMS Medicare Appeals Process Overview). Filing must occur within 60 days of the Appeals Council decision.

For an overview of the broader insurance appeals process, including non-Medicare tracks, the structural parallels across payer types are significant.

Causal Relationships or Drivers

Denials that generate appeals arise from identifiable, recurring determination categories. The most common denial basis in Original Medicare is lack of medical necessity, where the MAC applies Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) as benchmarks. When clinical documentation does not map to an applicable NCD or LCD, denial is nearly automatic.

OMHA's 2022 Congressional Justification noted that ALJ workloads have been driven substantially by Medicare Part C and Part D plan denials that escalate through all prior levels before reaching federal administrative review. The backlog at the ALJ level — which at its peak in 2015 exceeded 800,000 pending appeals — was directly attributable to Part C plan denial volumes outpacing hearing officer capacity (OMHA Congressional Justification, FY2023).

Formulary tier placement disputes under Part D are a secondary driver, particularly for specialty biologics where step therapy requirements generate denial patterns across large beneficiary populations. Coverage gap disputes and low-income subsidy (LIS) eligibility errors also generate significant appeal volumes at Levels 1 and 2.

The medical necessity appeals framework applies directly here — the clinical standards MAC contractors use are publicly posted and auditable.

Classification Boundaries

Medicare appeals divide into four structurally distinct tracks:

Original Medicare (Parts A and B): MACs conduct Level 1 redeterminations. QICs handle Level 2. All subsequent levels follow the OMHA/DAB pathway.

Medicare Advantage (Part C): Initial Organization Determinations (ODs) are made by the MA plan itself. Level 1 is a plan-level Reconsideration. Level 2 is an Independent Review Entity (IRE) reconsideration — contracted by CMS, not the plan. Levels 3–5 follow the same OMHA/DAB/federal court pathway as Parts A and B.

Part D (Prescription Drug): Initial Coverage Determinations are made by the plan. Level 1 is a plan Redetermination. Level 2 is an IRE. Levels 3–5 mirror the structure above. Formulary exception requests operate on a parallel but distinct sub-track prior to entering the formal appeals ladder.

Dual Eligibles: Beneficiaries enrolled in both Medicare and Medicaid face a layered appeals architecture. State Medicaid agency appeals processes may apply concurrently or sequentially depending on whether the denial originates from a Medicare-covered service or a Medicaid-wraparound benefit. This intersection is governed by both 42 C.F.R. Part 405 and 42 C.F.R. Part 438, as amended effective February 25, 2026. The 2026 amendments to 42 C.F.R. Part 438 introduced updated requirements for Medicaid managed care appeals and grievances, including strengthened notice standards, revised timeframes for plan-level resolutions, and expanded enrollee protections that affect how dual-eligible appeals are coordinated across Medicare and Medicaid managed care systems.

The types of insurance appeals taxonomy distinguishes between plan-level, independent review, and administrative law pathways — classifications that map directly onto the Medicare structure above.

Tradeoffs and Tensions

Speed vs. procedural completeness: Expedited appeals (available when standard timelines would seriously jeopardize health) compress review to 72 hours at the QIC level. The tradeoff is that expedited processes allow less time for detailed documentation submission, which can disadvantage appellants with complex clinical records.

AIC thresholds and access: The amount-in-controversy requirement for ALJ hearings ($180 in 2023) and federal court ($1,760 in 2023) structurally filters out low-dollar denials from advanced review. Aggregation rules allow providers to combine multiple claims to meet the AIC threshold (42 C.F.R. § 405.1006(b)), but individual beneficiaries generally cannot aggregate unrelated claims, creating an asymmetry between provider and beneficiary access to upper-level review.

Independent Review Entity independence: IREs at Level 2 for Parts C and D are contracted by CMS — meaning a federal agency contracts with private entities to conduct nominally independent review of federal health plan decisions. This structural relationship has been scrutinized in policy literature for potential conflicts of interest, though IREs are required to meet CMS accreditation standards.

ALJ backlog: OMHA's statutory 90-day target for ALJ decisions has been consistently unmet in high-volume periods. The ALJ average processing time reached 1,003 days in 2017 before CMS implemented operational changes, per OMHA annual reports (OMHA Adjudication Statistics).

Common Misconceptions

Misconception: Filing a grievance is the same as filing an appeal.
A grievance addresses quality-of-care complaints or plan conduct. An appeal challenges a specific coverage or payment determination. CMS regulations treat these as separate tracks with different filing mechanisms, timelines, and outcomes. Filing a grievance does not preserve appeal rights.

Misconception: Missed deadlines are always fatal.
42 C.F.R. § 405.942(b) and § 405.962(b) allow for good-cause extensions at Levels 1 and 2. Good cause must be documented and asserted in writing. The standard is not automatic — the MAC or QIC must accept the rationale — but extensions are available and are regularly granted.

Misconception: Providers cannot appeal on behalf of beneficiaries.
Providers who accept assignment have independent appeal rights. Additionally, an authorized representative — including a provider — can appeal on a beneficiary's behalf with a signed Appointment of Representative (Form CMS-1696) (CMS Form 1696).

Misconception: A favorable ALJ decision guarantees payment.
CMS retains the right to refer certain ALJ decisions to the Appeals Council for review on its own motion, even decisions favorable to the beneficiary. The Appeals Council can reverse, remand, or modify ALJ rulings.

Misconception: Part D formulary exceptions are appeals.
A formulary exception is a coverage determination request — a prerequisite step, not an appeal. Only after an exception request is denied does the formal appeal process begin. Conflating the two can cause beneficiaries to miss the actual appeal filing window.

For a detailed look at the urgent and expedited insurance appeals framework, the interaction between timeline compression and documentation requirements is examined across both Medicare and commercial contexts.

Checklist or Steps

The following sequence reflects the structural phases of a Medicare Part A/B appeal through Original Medicare. Steps for Parts C and D differ at Levels 1 and 2.

Phase 1: Receive and review the initial determination
- Obtain the Medicare Summary Notice (MSN) for Parts A/B, or the Explanation of Benefits (EOB) for Part C/D
- Identify the specific reason code(s) for denial
- Locate the applicable Local Coverage Determination (LCD) or National Coverage Determination (NCD) at CMS Coverage Database
- Confirm the filing deadline (120 days from MSN receipt for Level 1)

Phase 2: File the Level 1 Redetermination
- Complete or reference Form CMS-20027 (Redetermination Request)
- Attach supporting clinical documentation addressing the denial reason code
- Submit to the appropriate MAC identified on the MSN
- Retain proof of submission (certified mail or electronic confirmation)

Phase 3: Evaluate the MAC decision
- Review the Redetermination Notice within the 60-day MAC general timeframe
- If unfavorable, calculate the 180-day deadline for Level 2 QIC filing

Phase 4: File the Level 2 QIC Reconsideration
- Submit to the QIC identified in the Redetermination Notice
- Include all prior documentation plus any new clinical evidence
- Note: New evidence is generally not considered after Level 2 in certain Part C tracks

Phase 5: Assess AIC and ALJ eligibility
- Confirm the denied amount meets the annual ALJ threshold ($180 in 2023)
- File Form OMHA-100 within 60 days of QIC reconsideration notice
- Request a hearing (in-person, video, or telephone) or written decision

Phase 6: Medicare Appeals Council (if ALJ unfavorable)
- File written request to DAB within 60 days of ALJ decision
- No new evidence is submitted at this level; review is based on the existing record

Phase 7: Federal District Court (if AIC threshold met)
- File civil action within 60 days of Appeals Council decision
- Confirm the AIC meets the $1,760 federal court threshold (2023 figure)

Reference Table or Matrix

Part C vs. Part A/B Level Differences

Part D-Specific Pathway

References

• Centers for Medicare & Medicaid Services (CMS) — Medicare Appeals Process Overview
• Office of Medicare Hearings and Appeals (OMHA) — Adjudication Statistics
• [OMHA FY2023 Congressional Just